CO-TEKNOWLEDGE
9.4.2024 14:01:32 CEST | Business Wire | Press release
TeKnowledge marks its global debut today, bringing together the formidable strengths of Cytek Security, Tek Experts, and Elev8 into a single, unified powerhouse. Each entity contributes its specialized expertise—Cytek Security in cutting-edge cybersecurity readiness, Tek Experts in unparalleled enterprise technical managed services, and Elev8 in innovative technical skilling—creating a comprehensive portfolio under TeKnowledge that offers end-to-end digital transformation services. This strategic amalgamation heralds the beginning of a new era in tech services, where TeKnowledge stands as the transformative catalyst for digital evolution, providing governments and enterprises worldwide with unparalleled cybersecurity services, advanced technical skilling, and enterprise technical managed services at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240409688971/en/
TeKnowledge: Uniting Cytek Security, Tek Experts, and Elev8 under one banner to pioneer the future of secure digital transformation and tech talent empowerment across the globe (Graphic: Business Wire)
Backed by over a decade of pioneering achievements in the tech services industry and a distinguished roster of government and enterprise customers worldwide, TeKnowledge is uniquely equipped to navigate the complexities of digital modernization. By integrating these powerhouse brands, TeKnowledge tackles the critical challenges of bridging the tech talent gap and expediting digital imperatives, providing a holistic suite of services tailored to bolster cybersecurity defenses, cultivate essential technical skills, and deliver expert technical managed services to streamline and accelerate digital strategies.
Under the guidance of Aileen Allkins, President and CEO, TeKnowledge is pioneering new frontiers in digital services. Drawing upon her notable success at various tech giants including Microsoft and HP, Aileen has swiftly positioned TeKnowledge as a leader in secure and scalable technology solutions. In her first strategic initiative, Aileen has built an exceptional leadership team, merging seasoned executives from Tek Experts, Elev8, and Cytek, and enriched by strategic new appointments. This includes bringing on board Jyllene Miller as Chief Revenue and Growth Officer, tapping into her extensive experience in growth strategies and market development garnered at numerous Fortune 500 companies to propel TeKnowledge's global expansion. The team is further bolstered by Eric Schifflers as Chief Information Security Officer (CISO), whose vast experience across global organizations like NATO, Ria Money Transfer, and Roche, amplifies TeKnowledge's cybersecurity defenses and strategic security initiatives.
The executive leadership team at TeKnowledge, a dynamic group of seasoned leaders, embodies a wealth of diverse expertise, driving the company's strategic vision across public and private sectors. Their collective skills in global operations, cybersecurity, digital transformation, and customer experience, honed over decades, are crucial in navigating the digital landscape's complexities. This team's unified approach is setting new industry standards, establishing TeKnowledge as a leader in digital services and a catalyst for transformative growth and resilience in the digital era.
"A unified TeKnowledge signifies a major shift in digital transformation services," states Aileen Allkins, President and CEO. "Bringing together the expertise of Cytek Security, Tek Experts, and Elev8 under the TeKnowledge umbrella, creates a synergy that benefits our customers as we enhance our delivery, achieving faster, more impactful outcomes. This positions us to effectively tackle the tech talent gap and pace of digital innovation. Offering a comprehensive suite of elite cybersecurity services, top-tier digital skilling, and scalable technical managed services, TeKnowledge is committed to guiding governments and enterprises worldwide through the complexities of digital transformation. Our approach integrates these services seamlessly, maximizing efficiency, simplifying processes, and accelerating the achievement of strategic imperatives with unparalleled precision and efficacy."
How TeKnowledge is Bridging Global Divides with Local Impact:
- Optimized Managed Technical Services: TeKnowledge (f.k.a. Tek Experts) stands out with its superior operational excellence and agile solutions, supported by a global network of professionals, including a significant presence in emerging markets. Our enterprise managed services are distinguished by their ability to seamlessly integrate and scale, ensuring organizations achieve operational superiority and strategic success in the digital landscape.
- Precision Technical Skilling: Directly addressing the global talent gap, TeKnowledge's (f.k.a. Elev8) custom training programs are strategically designed to equip both the current and future generations with the skills needed to navigate and excel in the ever-evolving tech landscape, preparing them for the challenges and opportunities that lie ahead.
-
Dynamic Cybersecurity Services: With an all-encompassing suite of advisory and Managed Security Services (MSS) offerings, TeKnowledge (f.k.a. Cytek Security) equips customers with dynamic defenses against the evolving cyber landscape.
The launch of TeKnowledge heralds an important evolution in the global digital landscape, emphasizing a future where digital security and operational excellence transform from aspirations into baseline expectations worldwide. At the core of this transformation is the robust talent—engineers supporting engineers, and developers supporting developers—to ensure unparalleled expertise and collaboration in tackling the digital challenges ahead.
To learn more about TeKnowledge, visit www.TeKnowledge.com.
About TeKnowledge: Accelerating Progress, Securing Futures.
TeKnowledge stands as the transformative catalyst for digital evolution, enabling governments and enterprises worldwide to navigate the challenges with digital transformation today and tomorrow with elite cybersecurity implementation and managed security services (MSS), top-tier digital skilling, and technical managed services at scale. TeKnowledge envisions a world where every government and enterprise is empowered with the most advanced, secure, and accessible technology solutions. Our commitment to technology enablement, security, and advancement positions us uniquely in the market, ensuring our customers are equipped to achieve their strategic imperatives in the digital age with confidence and competitive advantage. Start your journey towards digital excellence by visiting TeKnowledge.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409688971/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom